Patents by Inventor Jeffrey A. Whitten

Jeffrey A. Whitten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220324879
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: October 13, 2022
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Publication number: 20220306652
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 11286264
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Patent number: 11286265
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 11155563
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 26, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Publication number: 20210214373
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Publication number: 20210087206
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Evan W. ROGERS, Jane UNG, Han ZHANG, Jeffrey WHITTEN, Dayong ZHAI, Wei DENG, Jingrong Jean CUI
  • Publication number: 20200392160
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: December 17, 2020
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 10745416
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 18, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Publication number: 20200190110
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 18, 2020
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Publication number: 20200157119
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: May 21, 2020
    Inventors: Jingrong Jean CUI, Evan W. ROGERS, Jane UNG, Jeffrey Whitten, Dayong Zhai, Wei DENG, Xin ZHANG, Zhongdong HUANG, Jing LIU, Han ZHANG
  • Publication number: 20090264423
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: August 31, 2007
    Publication date: October 22, 2009
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Peter CHUA, FABRICE PIERRE, JEFFREY WHITTEN
  • Patent number: 7490569
    Abstract: A fabric is provided having discrete surface portions of a primary backing and tufted yarns exposed on the technical face of the fabric. To form the fabric, the yarn feed controlled by servomotors is adjusted in increments to rob back yarn sufficient to pull out the previously tufted loops in selected portions of the fabric, leaving the primary backing portion of the pulled-out loops exposed on the technical face. By the selection process, random or patterned tufted portions and exposed primary backing surface portions are provided on the technical face of the fabric.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: February 17, 2009
    Assignee: Mohawk Brands, Inc.
    Inventors: Jeffrey A. Whitten, Gene C. Duff, Robert D. Hutchison
  • Publication number: 20070293485
    Abstract: Provided herein are methods for administering an efficacious amount of a compound of Formula I that reduce the severity of a potential adverse effect or obviate a potential adverse effect.
    Type: Application
    Filed: June 1, 2007
    Publication date: December 20, 2007
    Inventors: John Lim, Jeffrey Whitten
  • Publication number: 20070117770
    Abstract: Provided herein are isolated nucleic acids that comprise a human rRNA or rDNA subsequence and related compositions and methods of use.
    Type: Application
    Filed: August 18, 2006
    Publication date: May 24, 2007
    Applicant: Cylene Pharmaceuticals, Inc.
    Inventors: Denis Drygin, Emil Michelotti, Sean O'Brien, William Rice, Adam Siddiqui-Jain, Jeffrey Whitten
  • Publication number: 20070043039
    Abstract: The present invention relates to methods for ameliorating a cell proliferative disorder using quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents.
    Type: Application
    Filed: May 10, 2006
    Publication date: February 22, 2007
    Inventors: Jeffrey Whitten, Michael Schwaebe, Adam Siddiqui-Jain, Terrance Moran
  • Publication number: 20070010512
    Abstract: The present invention relates to 1,4-dihydro-4-oxo-1,8-napthpyridine analogs of the formula and pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein A, X, W and Y are substituents. The present invention also relates to methods for using such compounds.
    Type: Application
    Filed: June 27, 2005
    Publication date: January 11, 2007
    Inventors: Jeffrey Whitten, Michael Schwaebe, Terence Moran
  • Publication number: 20060264634
    Abstract: The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, W, X, Z, B, L, R1, R3, R4 and R5 are substituents. The present invention also relates to methods for using such compounds.
    Type: Application
    Filed: April 14, 2006
    Publication date: November 23, 2006
    Inventors: Jeffrey Whitten, Fabrice Pierre, Michael Schwaebe
  • Publication number: 20060229303
    Abstract: The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.
    Type: Application
    Filed: March 28, 2006
    Publication date: October 12, 2006
    Inventors: Jeffrey Whitten, Michael Schwaebe, Adam Siddiqui-Jain, Terrance Moran
  • Patent number: 7033661
    Abstract: A fabric is provided having discrete surface portions of a primary backing and tufted yarns exposed on the technical face of the fabric. To form the fabric, the yarn feed controlled by servomotors is adjusted in increments to rob back yarn sufficient to pull out the previously tufted loops in selected portions of the fabric, leaving the primary backing portion of the pulled-out loops exposed on the technical face. By the selection process, random or patterned tufted portions and exposed primary backing surface portions are provided on the technical face of the fabric.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: April 25, 2006
    Assignee: Mohawk Brands Inc.
    Inventors: Jeffrey A. Whitten, Gene C. Duff, Robert D. Hutchison